Evidence map›Paper›PMID 24998139›Full record

ArticleOral oncology2014

Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy.

M Vatca, J T Lucas, J Laudadio, R B D'Agostino, J D Waltonen, C A Sullivan, R Rouchard-Plasser, M Matsangou, J D Browne, K M Greven and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 5 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. The prevalence of oral mucositis after radiotherapy in patients with Head and Neck Cancer and its associated factors: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  3. The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  4. Pooled it
  5. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  6. From clinic to couch: a pilot study of home-use photobiomodulation for radiation-induced oral mucositis and dermatitis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  7. Trial
  8. Clinicopathological and biobehavioral factors influence the onset and severity of oral mucositis in patients with head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  9. Prophylactic photobiomodulation to reduce oral mucositis in head and neck cancer: an observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Confounding factors in the assessment of oral mucositis in head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Review
  18. Article
  19. Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

M VatcaSection on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mvatca@wakehealth.edu.
J T LucasDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jolucas@wakehealth.edu.
J LaudadioDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jlaudadio@uams.edu.
R B D'AgostinoDepartment of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: rdagosti@wakehealth.edu.
J D WaltonenComprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA; Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jwaltone@wakehealth.edu.
C A SullivanComprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA; Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: csulliva@wakehealth.edu.
R Rouchard-PlasserDepartment of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: rplasser@wakehealth.edu.
M MatsangouSection on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mmatsang@wakehealth.edu.
J D BrowneDepartment of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: jdbrowne@wakehealth.edu.
K M GrevenDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: kgreven@wakehealth.edu.
M PorosnicuSection on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mporosni@wakehealth.edu.
Wake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197NCI NIH HHS P30CA012197
6 · The paper itself

Abstract

objectivesThe standard concurrent radiotherapy and chemotherapy regimens for patients with oropharyngeal cancer are highly toxic. Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has recently emerged as a distinct biological and clinical entity with improved response to treatment and prognosis. A tailored therapeutic approach is needed to optimize patient care. The aim of our study was to investigate the impact of HPV and smoking status on early toxicities (primarily mucositis) associated with concurrent chemotherapy and radiotherapy in patients with OPSCC. MATERIALS AND

methodsWe retrospectively evaluated 72 consecutive patients with OPSCC and known HPV status treated with concurrent radiotherapy and chemotherapy at our institution. Treatment-related toxicities were stratified by smoking and HPV status and compared using univariate and multivariate logistic regression.

resultsHPV-positive patients had a 6.86-fold increase in the risk of having severe, grade 3-4 mucositis. This effect was preserved after adjusting for patient smoking status, nodal stage, radiotherapy technique and radiotherapy maximum dose. Additionally, HPV status had significant effect on the objective weight loss during treatment and at three months after treatment. Consistently, non-smokers had a significant 2.70-fold increase in the risk of developing severe mucositis.

conclusionRisk factors for OPSCC modify the incidence of treatment-related early toxicities, with HPV-positive and non-smoking status correlating with increased risk of high grade mucositis and associated outcomes. Retrospective single-institution studies need to be interpreted cautiously. However, this finding is important to consider when designing therapeutic strategies for HPV-positive patients and merits further investigation in prospective clinical trials.

Indexed as

SmokingAdultAgedAged, 80 and overAlphapapillomavirusAntineoplastic AgentsCombined Modality TherapyDisease-Free SurvivalFemaleHumansMaleMiddle AgedMucositisOropharyngeal NeoplasmsPatient ComplianceRadiotherapyAntineoplastic AgentsChemotherapyHuman papillomavirusOral mucositisRadiotherapySmokingSquamous cell of head and neck

Identifiers

PMID24998139
PMCPMC4148719
OpenAlexW2125902870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.